{‘She possesses little expertise’: the US scientific field braces for Dr. Høeg's role at the Food and Drug Administration.

Given that the US continues making sweeping changes to its vaccine schedules, one figure appears somewhat surprisingly: Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines during the global health crisis and has concentrated on alleged deaths following COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Vaccine Program

Agency leaders planned to unveil sweeping changes to the pediatric vaccine schedule in December, bringing the US with the Danish national calendar, it is understood – a major change that would place the US out of step with much of the international standard with little proof for improved outcomes. The announcement has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is scheduled to present at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing immunizations at the FDA.

Høeg has often pushed for halting some pediatric immunization guidelines in the US so as to align more like Denmark's approach, a nation with comprehensive healthcare and a population about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Background

The appointee has no apparent background in drug development, approval processes or management, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for running the CDER, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Past heads of CBER would “be deeply familiar with legal statutes and the science of drug development”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that previous people who led the center have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the generic program clears numerous generic drugs. There’s a biologic copycat branch, OTC medication office and more, and every single one need to be managed,” she explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the job, which supervises more than 5,000 personnel. “It is a enormous management job, if you do it right,” she said.

Agency Reaction and Contentious Programs

In response to concerns about Høeg’s credentials and whether this selection represents more teamwork among FDA leaders on vaccines, a representative responded that the “inquiries stem from inaccurate presumptions”.

“This background aligns with the duties of her role,” the spokesperson explained, citing the period Høeg spent advising the agency head on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s new priority voucher program, a disputed one-day drug-approval program that allegedly worried her former heads. “How are these drugs being selected for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the agency seems to be moving towards laxer regulations of most medications, aside from vaccines.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, track record, some experts said. She released a study using unverified volunteer-provided data to determine the incidence of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming federal leadership encompassed altering rules for recently developed shots and halting “optional” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has according to sources floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She is an all-around true believer who begins with her preconceived notions and reverse-engineers to retrofit the science in a extremely deceptive, untruthful fashion,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of fellow skeptics, {like|